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Background: The aim of the present study was to assess manifestations of and applied treatment concepts for
females with Fabry disease (FD) according to the current European Fabry Guidelines.
Methods: Between 10/2008 and 12/2014, data from the most recent visit of 261 adult female FD patients from six
German Fabry centers were retrospectively analyzed. Clinical presentation and laboratory data, including plasma
lyso-Gb3 levels were assessed.
Results: Fifty-five percent of females were on enzyme replacement therapy (ERT), according to recent European FD
guidelines. Thirty-three percent of females were untreated although criteria for ERT initiation were fulfilled. In
general, the presence of left ventricular hypertrophy (LVH) seemed to impact more on ERT initiation than impaired
renal function. In ERT-naïve females RAAS blockers were more often prescribed if LVH was present rather than
albuminuria. Affected females with missense mutations showed a similar disease burden compared to females with
nonsense mutations. Elevated plasma lyso-Gb3 levels in ERT-naïve females seem to be a marker of disease burden,
since patients showed comparable incidences of organ manifestations even if they were ~8 years younger than
females with normal lyso-Gb3 levels.
Conclusion: The treatment of the majority of females with FD in Germany is in line with the current European FD
guidelines. However, a relevant number of females remain untreated despite organ involvement, necessitating a
careful reevaluation of these females.
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Fabry disease (FD; OMIM #301500) is an X-linked
(Xq22.1) inborn error of glycosphingolipid degradation
resulting from deficient α-galactosidase A activity (GLA;
300644) due to mutations in the GLA gene. Fabry-
specific manifestations result from systemic lysosomal
accumulation of mainly globotriaoslyceramide (Gb3) [1].
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threatening arrhythmia, myocardial infarction, or cardiac
and renal failure, leading to a reduced life expectancy
[1]. Enzyme replacement therapy (ERT) with recombin-
ant GLA, including agalsidase-alfa (Replagal, Shire) and
agalsidase-beta (Fabrazyme, Genzyme) results in subcel-
lular Gb3 clearance, leading to stabilization or at least
slowing of disease progression in males and females
[2–11]. While the onset of first symptoms (Fabry-as-
sociated pain, angiokeratoma, abdominal pain, cornea
verticillata, hypo- or anhidrosis) in affected hemizy-
gous males with low or absent enzymatic GLA activ-
ity starts in early childhood, heterozygous femalele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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set, severity, and progression. Because of this heteroge-
neous clinical picture in females, the optimal time point
for ERT initiation still remains controversial.
Current FD guidelines and recommendations suggest
ERT initiation in females with FD after the onset of first
FD-typical renal, cardiac, and/or cerebral complications,
or in rapidly progressive disease [12, 13]. According to
Biegstraaten and colleagues, ERT should be considered
in females with classical and non-classical phenotype if
albuminuria/proteinuria, an estimated glomerular filtra-
tion rate (eGFR) <90 ml/min/1.73 m2, cardiac hyper-
trophy, signs of cardiac rhythm disturbances, cerebral
white matter lesions, transient ischemic attack or stroke,
FD-related pain or gastrointestinal (GI) symptoms are
present [13].
However, since ERT is assumed to be most effective
when started early before the onset of fibrosis or other
irreversible tissue damage [14–16], this strategy might
result in a therapeutic dilemma. Therefore, plasma lyso-
Gb3 has been discussed as a prognostic marker for dis-
ease severity and progression. While this concept is
established in males, the clinical relevance of lyso-Gb3
for female patients is still unclear [17–19].
In the Multicenter Female Fabry Study (MFFS), we
retrospectively analyzed a cohort of 261 genetically con-
firmed adult female FD patients from six German Fabry
centers to investigate the current ERT treatment status
and the implementation of the latest European FD rec-
ommendations [13] concerning treatment strategies.
Methods
Study design and patients
Between 10/2008 and 12/2014, 261 genetically con-
firmed adult female FD patients were consecutively re-
cruited or identified by family screenings (index patients
were either affected males or females) at Fabry centers
of the University Hospitals in Muenster, Wuerzburg,
Mainz, Cologne, Rostock, and the Charité Berlin. Patients
were retrospectively analyzed in an open cohort study. A
comprehensive diagnostic work-up was performed in all
centers including medical history and cardiac, renal, and
neurological evaluation. Data documentation followed the
clinical practice of the German Fabry Expert Centers for a
rare multisystemic disorder. The detailed clinical work-up
of patients has been reported elsewhere [20]. Gastrointes-
tinal pain includes abdominal pain, tenesmus, or cramping
more than once a week. Diarrhea was defined as ≥1 day/
month with three loose bowels or >250 g of stool weight
per day. Fatigue was defined by the Fukuda criteria [21].
Cardiac assessment included echocardiography and elec-
trocardiography. Left ventricular hypertrophy (LVH) was
defined as a septal diameter of >12 mm. Renal function
was quantified by the eGFR using the Chronic KidneyDisease-Epidemiology Collaboration equation (CKD-
EPI) [22] and the albumin-to-creatinine ratio (ACR)
from spot urine. Renal impairment was defined as
eGFR <90 ml/min/1.73 m2 according to “Kidney Dis-
ease: Improving Global Outcomes” (KDIGO) [23] and
European FD [13] guidelines and albuminuria as ACR
>30 mg albumin per g creatinine (microalbuminuria,
30–300 mg/g; macroalbuminuria >300 mg/g). All pa-
tients underwent neurologic examination and a clinical
interview focusing on a history of cerebral stroke or transi-
ent ischemic attack (TIA). Additionally, the presence of
FD-related pain was investigated [24]. In a subset of pa-
tients with a characteristic history of acral pain and/or dys-
esthesias, small fiber neuropathy (SFN) was diagnosed
additionally using quantitative sensory testing (QST) [25]
and/or by determination of the intraepidermal nerve fiber
density in skin biopsies [26, 27]. Disease severity was
assessed using the Mainz Severity Score Index (MSSI) [28].
Additional medication was assessed for the current visit.
Renin-angiotensin-aldosterone-system (RAAS) blockers in-
clude the prescription of angiotensin-converting enzyme
blockers, angiotensin receptor blockers, renin blockers,
as well as aldosterone antagonists. Diuretics include the
prescription of high ceiling/loop diuretics, thiazides,
carbonic anhydrase inhibitors, potassium-sparing di-
uretics. Analgesic drugs include the prescription of opi-
oids, anticonvulsants, selective serotonin reuptake
inhibitors, and non-steroidal anti-inflammatory drugs.GLA sequencing, measurement of GLA activity and
plasma lyso-Gb3
Genotyping for GLA gene mutations was performed by
direct sequencing of all seven coding exons including adja-
cent intron-exons boundaries as previously reported [29].
The following described mutations/variations were de-
tected: p.A20P, p.W24*, p.N34S, p.G35E, p.A37T,
p.P40L, p.M42V, p.L45P, p.H46R, p.R49G, p.C53S,
p.C63Y, p.I91T, p.C94S, p.R112C, p.R112H, p.R118C,
p.A121T, p.S126G, p.S128G, p.L129P, p.L131P, p.A135V,
p.N139S, p.A143T, p.G147R, p.Y151*, p.W162G,
p.L167Q, p.C172Y, p.Y173*, p.G183S, p.M187R,
p.M187V, p.W204*, p.K213M, p.N215S, p.R220*,
p.N224S, p.R227Q, p.R227*, p.D231N, p.W236C,
p.I242V, p.W262C, p.W262*, p.P265L, p.L268S,
p.V269A, p.A288D, p.R301P, p.R301Q, p.R301*,
p.D313Y, p.V316G, p.I319T, p.N320I, p.Q321*, p.Q327R,
p.Q327E, p.G328R, p.E338X, p.W340*, p.R342Q,
p.R342*, p.A350P, p.Q357*, p.W399*, IVS2 + 1G > T,
IVS2 + 1G > A, IVS5 + 1G > A, IVS6 + 1G > A. An over-
view of newly detected GLA mutations is presented
within the supplement (Additional file 1: Table S1). Fe-
males with genetic variants of unknown significance
(GVUS) and polymorphisms (i.e. p.R112H; p.N139S;
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calculations.
Nonsense mutations have been defined as single nucleo-
tide exchanges, resulting in stop codons (termination), de-
letions or insertions of nucleotides resulting in a frame
shift or large deletions within the protein, or splice site
mutations, resulting in altered splice products of mRNA.
GLA activity in leukocytes was determined using 4-
methylumbelliferyl-α-D-galactopyranoside (Santa Cruz
Biotechnology, Heidelberg, Germany) as previously de-
scribed [30]. Nacetylgalactosamine (Santa Cruz Biotech-
nology) was used as specific inhibitor of endogenous α-
galactosidase B activity [31]. GLA enzyme activity was
determined as nanomoles (nmol) of substrate hydro-
lyzed per hour (h) per mg protein and expressed as %
of reference. For plasma lyso-Gb3, lyso-ceramide was
used as reference (Matreya LLC, Pleasant Gap, PA,
USA) and D5-fluticasone propionate (EJY Tech, Inc.,
Rockville, Maryland, USA) served as internal standard.
Plasma lyso-Gb3 levels (reference 0.9–2.3 ng/ml) were
measured at the University of Rostock (A. Rolfs), and at
the University of Mainz (K. Lackner), Germany. To de-
termine if patients were below or above these reference
limits, each individual plasma lyso-Gb3 value was com-
pared with the internal reference at the time-point of
lyso-Gb3 determination.
Statistical analysis
Two-hundred sixty-one patients from the participating
FD centers were included in the analysis. If not stated
otherwise, continuous variables are expressed as mean
with standard deviation or median with range. Categor-
ical data is expressed as numbers and relative frequen-
cies in percent. A quality control of assessed data is
given in the supplement (Additional file 2: Table S2). An
overall data completeness of 88.9 % was achieved. To
deal with missing data, analyses were performed with an
as-is state for every parameter. Differences between
groups were analyzed with the unpaired Student’s t or
Mann-Whitney U test for continuous data, and the Fish-
er’s exact test for categorical data. Statistical significance
was considered at a 2-sided p < 0.05. All results areFig. 1 Overview of the participating FD centers and the distribution of fem
within the study (across all centers), or within each participating centerreported with their respective 95 % confidence intervals
(CI). SAS version 9.3 (SAS Institute Inc., Cary, North
Carolina, USA) and GraphPad PRISM V5.0 software
(GraphPad Software Inc., La Jolla, CA, USA) were used
for all statistical analyses.
Results
Clinical characterization of female patients with Fabry
disease
Between 10/2008 and 12/2014 a total of 261 genetically
confirmed adult (≥18 years) female FD patients pre-
sented at the participating Fabry centers in Muenster,
Wuerzburg, Mainz, Cologne, Berlin, and Rostock. Since
the presence of GVUS and polymorphisms might influ-
ence the outcome, females (n = 37) with these variants
were excluded (i.e. p.R112H, n = 1; p.N139S, n = 8;
p.A143T, n = 18; p.D313Y, n = 10). At the time of last
visit and data analysis, 127 (56.7 %) females received
ERT (i.e. agalsidase-alfa n = 108 [85.0 %], or agalsidase-
beta n = 19 [15.0 %]. The general ERT treatment status
differed across centers from 46.2 to 77.8 % females on
ERT (Fig. 1).
Since the treatment period of patients overlapped with
the worldwide agalsidase-beta shortage and a switch of
product might have an influence on treatment outcome
[11, 20], we assessed all changes in treatment regimens.
During agalsidase-beta shortage, nearly all females (18
from 19) under agalsidase-beta received a dose-reduction
(0.5 mg/kg body weight) or switched to agalsidase-alfa
until re-switch to full agalsidase-beta dose (1.0 mg/kg
body weight). From those who received agalsidase-alfa at
data assessment (n = 108), 20 patients had been switched
from agalsidase-beta to -alfa. Consequently, in this “real
world” study, both groups were not directly comparable.
However, analysis of the clinical presentation revealed
that patients under agalsidase-beta tended to be older
(p = 0.1371) and showed a trend towards a longer ERT
duration (p = 0.1499) than patients receiving agalsidase-
alfa (Additional file 3: Table S3). There were no signifi-
cant differences between the two patient groups (Additional
file 4: Table S4), except for angiokeratoma, NYHA clas-
ses, left ventricular diastolic diameter, resulting in aale patients. Numbers and frequencies (%) show either distributions
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(Additional file 4: Table S4). To analyze whether pa-
tients were treated in accordance with current European
FD guidelines [13] (class I: ERT is recommended; class
IIA/B: ERT should/may be considered) at the onset of first
organ manifestations, we analyzed the presence of at least
one of these manifestations in different organs (cardiac:
LVH, renal: eGFR <90 ml/min/1.73 m2, CNS: stroke/TIA,
pain: FD-related neuropathic pain, gastrointestinal: gastro-
intestinal symptoms) justifying ERT indication according
to classes I to IIA/B [13]. Following this stratification we
classified the females into 4 groups: 1) females on ERT
with indication (n = 124 [55.4 %]), 2) females without ERT
with indication (n = 76 [33.9 %]), 3) females on ERT
without indication (n = 3 [1.3 %]), 4) females without
ERT without indication (n = 21 [9.4 %]) (Table 1,
Fig. 2a). Since 34 % of females were not on ERT,
although an indication was identified, we further com-
pared treated and untreated females with indications for
ERT to identify differences between the two groups. The
group of females on ERT (mean treatment duration:
68 ± 48 months) was older, and tended to comprise
more patients with nonsense mutations (p = 0.0502),
more patients with plasma lyso-Gb3 levels above the
reference level, and more patients on additional medi-
cation (renin-angiotensin-aldosterone-system [RAAS]
blockers, diuretics, analgesics) than females not re-
ceiving ERT (Table 1). Evaluation of clinical presenta-
tion further revealed that female patients on ERT
showed a higher frequency of FD-typical signs and
symptoms, such as angiokeratoma, edema (ankle), tin-
nitus, hypacusis, FD-related pain, and fatigue (Table 1).
Patients on ERT suffered more often from stroke and
demonstrated a higher MSSI score (Table 1). Evaluation of
organ manifestations also showed that patients on ERT
suffered more often from a cardiac involvement, resulting
in higher frequencies of dyspnea and abnormalities in
electrocardiogram (ECG) (defined as T-wave negativa-
tion). They presented with higher NYHA classes, had in-
creased septal diameters, and higher frequencies for
concentric LVH (RR: 1.69 95 % CI 1.37 to 2.08; p < 0.0001;
Table 2). Renal measures showed that patients on ERT
also had a more severe renal impairment in that creatin-
ine- and cystatin C-based eGFR values were severely de-
creased and showed a difference of >15 ml/min/1.73 m2
compared to non-treated female patients (Table 2). Due to
the observed differences in eGFR, more patients on ERT
were assigned to CKD stage ≥2 than patients not on ERT
(RR: 1.70 95 % CI 1.29 to 2.24; p = 0.0003; Table 2). Inter-
estingly, the general frequencies of patients with albumin-
uria were similar, although patients on ERT comprised
more patients with macroalbuminuria (Table 2). Females
on ERT presented with significantly more manifestations
in different organs indicating ERT start [13] thanuntreated patients (2.5 [1–5] vs 1 [1–3], p < 0.0001;
Table 2, Fig. 2b).
To further investigate whether patients with nonsense
mutations have a higher disease severity, we compared
patients with missense and nonsense mutations separ-
ately from their ERT status (Table 3). All patients
showed at least one manifestation justifying ERT treat-
ment according to current guidelines [13]. Patients on
ERT with nonsense mutations had a longer treatment
duration than patients with missense mutations (Table 3).
Furthermore, patients with nonsense mutations more
often had elevated plasma lyso-Gb3 levels and angioker-
atoma, and showed a trend towards more edema (ankle)
(p = 0.0541; Table 3). However, no further significant dif-
ferences in clinical presentation and cardiac as well as
renal measures have been detected (Table 3). Also, pa-
tients showed no differences for additional medication
with RAAS blockers, diuretics, or analgesics.
Untreated patients carrying nonsense mutations were
slightly but not significantly younger than patients with
missense mutations. Although untreated patients with
nonsense mutations demonstrate more often a reduced
GLA activity and tended to have higher plasma lyso-Gb3
levels (p = 0.0505), no further clinical differences in the
group of patients without ERT have been detected
(Table 3).
Plasma lyso-Gb3 in ERT-naïve females with FD
Since the biomarker lyso-Gb3 correlates well with dis-
ease manifestation and progression in male FD patients,
we analyzed whether differences in plasma lyso-Gb3
levels might also explain differences in FD-specific mani-
festations and symptoms in female patients. Therefore,
we compared ERT-naïve females (independent of a
manifestation that would indicate ERT) with lyso-Gb3
levels below the reference value (n = 16) with those
above the reference value (n = 52) (Table 4). Females
with lyso-Gb3 levels above the reference were younger
than patients with normal lyso-Gb3 levels (41 ± 13 vs.
49 ± 15 years; p = 0.0299). Females with elevated lyso-
Gb3 levels comprised more patients with nonsense mu-
tations (Table 4). Furthermore, females with elevated
lyso-Gb3 levels suffered more often from FD-related
pain (Table 4). Interestingly, evaluation of further FD-
typical symptoms as well as cardiac and renal measures
showed no intergroup differences. Also, the prescription
of additional medication was similar in both groups.
However, patients with elevated lyso-Gb3 levels tended
to a higher albumin-creatinine-ratio (ACR; p = 0.0530;
Table 4).
Discussion
The aim of our multicenter study was to investigate the
current ERT treatment status and the implementation of












N 124 (55.4) 76 (33.9) 3 (1.3) 21 (9.4) 224
Age [y] 53 ± 14**** 43 ± 14 44 ± 9 35 ± 13 48 ± 15
Weight [kg] 71.0 ± 17.1 69.9 ± 17.5 66.2 ± 11.2 66.6 ± 19.6 70.1 ± 17.4
Height [cm] 164.5 ± 6.7 165.8 ± 13.8 164.0 ± 4.3 166.7 ± 6.2 165.1 ± 9.1
Heart rate [bpm] 69 ± 13 69 ± 11 63 ± 7 67 ± 8 69 ± 12
SBP [mmHg] 122 ± 17 123 ± 14 126 ± 5 115 ± 16 122 ± 16
DBP [mmHg] 74 ± 9 77 ± 9 76 ± 1 73 ± 10 75 ± 9
Nonsense mutation [n] 59 (50.0) 25 (34.7) 0 (0.0) 4 (19.1) 88 (41.1)
α-galactosidase A activity [% reference] 118 ± 109 118 ± 95 127 ± 74 135 ± 72 119 ± 101
α-galactosidase A activity below reference [n] 42 (56.0) 24 (53.3) 1 (33.3) 3 (42.9) 70 (53.9)
Lyso-Gb3 value [ng/ml] 7.5 ± 6.5 7.9 ± 5.8 4.5 ± 0.3 5.2 ± 4.6 7.4 ± 6.1
Lyso-Gb3 value above reference [n] 70 (94.6)** 43 (78.2) 2 (100.0) 9 (69.2) 124 (86.1)
Pts on RAAS blockers [n] 66 (57.4)**** 16 (23.9) 0 (0.0) 3 (18.8) 85 (42.3)
Pts on diuretic drugs [n] 45 (39.1)**** 5 (7.7) 0 (0.0) 1 (5.9) 51 (52.5)
Pts on analgesic drugs [n] 37 (35.2)*** 7 (10.5) 0 (0.0) 0 (0.0) 44 (22.9)
ERT since [months] 68 ± 48 0 ± 0 43 ± 34 0 ± 0 38 ± 49
Angiokeratoma [n] 59 (49.6)** 20 (27.4) 2 (66.7) 3 (15.0) 84 (39.1)
Edema [n] 28 (22.6)**** 1 (1.4) 0 (0.0) 0 (0.0) 29 (13.3)
Gastrointestinal pain [n] 32 (26.2) 26 (36.6) 0 (0.0) 0 (0.0) 58 (27.1)
Diarrhea [n] 33 (27.0) 13 (18.8) 0 (0.0) 0 (0.0) 46 (21.8)
Hypohidrosis [n] 49 (40.5) 22 (29.3) 2 (66.7) 1 (5.0) 74 (33.8)
Cornea verticillata [n] 76 (65.5) 29 (55.8) 2 (66.7) 6 (42.9) 113 (61.1)
Tinnitus [n] 42 (34.2)* 13 (18.1) 1 (33.3) 2 (9.5) 58 (26.5)
Hypacusis [n] 27 (22.0)* 7 (9.9) 1 (33.3) 0 (0.0) 35 (16.1)
FD-related pain [n] 82 (66.1)* 37 (49.3) 0 (0.0) 0 (0.0) 119 (53.6)
Neuropathic pain [n] 40 (32.8)*** 7 (9.7) 0 (0.0) 0 (0.0) 47 (21.7)
Fatigue [n] 62 (51.2)**** 15 (20.0) 1 (33.3) 0 (0.0) 78 (35.6)
Ever stroke/TIA [n] 29 (23.4)* 7 (9.2) 0 (0.0) 0 (0.0) 36 (16.1)
SFN [n] 22 (29.3) 9 (15.0) 0 (0.0) 2 (12.5) 33 (21.7)
Disease severity score
MSSI score 20.7 ± 10.8**** 7.3 ± 5.2 7.3 ± 5.0 1.5 ± 1.5 14.7 ± 11.4
Categorical data are presented as n and are % of total in parenthesis. Otherwise data is presented as mean ± standard deviation. eGFR: estimated glomerular
filtration rate (aexcluding patients with dialysis and/or kidney transplant). DBP: diastolic blood pressure; MSSI Mainz Severity Score Index, Pts patients, RAAS
renin-angiotensin-aldosterone-system, SBP systolic blood pressure, SFN small fiber neuropathy, TIA transitory ischemic attack
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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male patients with FD in Germany.
Our main findings are: 1) Fifty-seven % of female FD
patients in Germany were under ERT, nearly all (except
three females) presented with different organ manifesta-
tions that justify ERT initiation according to current
European guidelines [13]; 2) one third of females
remained without ERT, although indications (organ
manifestations) for ERT initiation were fulfilled; 3) the
presence of LVH seems to impact more on ERT initi-
ation than impaired renal function; 4) in ERT-naïvefemales the prescription of RAAS blockers is mostly
consistent with the presence of LVH, but not with
albuminuria; 5) once affected females with missense
mutations show similar disease burden compared to
females with nonsense mutations; 6) elevated plasma
lyso-Gb3 levels in ERT-naïve females seem to be a
marker of disease burden, since these patients showed
comparable incidences of organ manifestations and a
higher frequency of FD-related pain even if they were
~8 years younger than females with normal lyso-Gb3
levels.
Fig. 2 Differences between patients with and without ERT at least one organ manifestation justifying ERT according to current guidelines.
a Distribution of manifestations in different organs justifying ERT with class I (ERT is recommended) and class IIA/B (ERT should/may be
considered) recommendations. b Accumulation of different organ manifestations justifying ERT. Females may present with one to five
different manifestations (green, yellow, orange, red, black represent 1, 2, 3, 4, 5 simultaneous manifestations, respectively). Cardiac:
presence of left ventricular hypertrophy; Renal: eGFR <90 ml/min/1.73 m2; CNS: stroke/ transient ischemic attack; Pain: neuropathic/FD-
related pain; GI: gastrointestinal symptoms (diarrhea, abdominal pain)
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clinically well established, since patients often suffer
from a FD-typical organ involvement and/or display ab-
normal biomarkers (i.e. low or absent GLA activity, high
plasma lyso-Gb3 values). In contrast, the optimal time
point for ERT initiation in females with FD, often classi-
fied as “only” asymptomatic or minor symptomatic car-
riers still remains unclear, as their disease manifestations
and progression, as well as biomarker levels are diverse.
Most guidelines recommend ERT initiation in females
with FD as soon as FD-typical organ manifestations such
as LVH, renal insufficiency, or clinical events such as
TIA or stroke appear [12, 13]. Our analysis of 224 fe-
males with FD may reflect an average of women with FD
in Germany. About 55 % of the affected females are on
ERT, confirming the prevalence of 53 % reported in the
Fabry Outcome Survey (FOS) registry (FOS Investigator
report 2012–2013) and suggesting that the reported
prevalence of 34 % treated females within the Fabry
Registry [32, 33] might be too low, at least for Germany.
Of those patients receiving ERT, nearly all showed at
least one organ manifestation defined as LVH, an eGFR
<90 ml/min/1.73 m2, cerebral complications, pain, or GI
symptoms indicating ERT. Concerning this aspect, the
treatment concept for females with FD in Germany is in
line with the current European FD recommendations
and guidelines [13]. Nevertheless, still one third of ERT-
naïve female patients suffered from at least one clinicallyrelevant organ manifestation. Even if the observed LVH,
renal insufficiency, or stroke and/or TIA might also be
due to comorbidities and, more importantly, some pa-
tients refuse ERT, or can’t receive ERT due to pregnancy
or future family planning, the remaining number of clin-
ically not justifiable untreated affected females seems to
be relevant. As mentioned before, one reason for the
relatively high frequency of ERT-untreated females with
mild renal involvement only might be that many physi-
cians did not recognize these females as patients at risk.
In clinical practice, these patients may benefit from
RAAS blockers. If under this treatment and with comor-
bidities/ risk factors (such as arterial hypertension) well-
controlled, renal function still declines, ERT should be
initiated. The high incidence and increased risk for LVH
in patients on ERT indicates that the presence of LVH
seems to impact more on ERT initiation than impaired
renal function. These observations urge the need for a
more stringent implementation of the new European FD
guidelines for females across centers and reevaluation of
untreated females. Furthermore, some female patients
refusing ERT might benefit from future chaperone treat-
ment strategies [34].
Renal biopsies demonstrate that even in children Gb3
accumulation within podocytes affects foot process efface-
ment without presence of albuminuria, indicating an early
Fabry nephropathy [35]. In fact, several studies suggest a
better benefit when ERT is started at an early disease stage
Table 2 Cardiac and renal parameters









Dyspnea [n] 54 (43.6)*** 14 (18.7) 0 (0.0) 1 (4.8) 69 (30.9)
NYHA class [n]
none 29 (28.2) 31 (45.6)* 1 (50.0) 9 (56.3) 70 (37.0)
I 34 (33.0) 25 (36.8) 1 (50.0) 6 (37.5) 66 (34.9)
II 27 (26.2) 11 (16.2) 0 (0.0) 1 (6.3) 39 (20.6)
III 13 (12.6)** 1 (1.5) 0 (0.0) 0 (0.0) 14 (7.4)
IV 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
LV diastolic diameter [mm] 45.8 ± 5.5 46.2 ± 4.4 42.5 ± 3.5 46.4 ± 7.2 46.0 ± 5.3
LV systolic diameter [mm] 28.8 ± 6.1 28.5 ± 4.7 24.0 ± 1.4 29.7 ± 4.9 28.7 ± 5.5
LVDDi [cm/m2] 2.79 ± 0.33 2.83 ± 0.68 2.58 ± 0.12 2.78 ± 0.42 2.81 ± 0.49
Septal diameter [mm] 12.3 ± 3.6**** 9.6 ± 2.0 9.5 ± 2.1 8.4 ± 1.5 11.0 ± 3.3
LVH [n] 64 (55.7)**** 14 (18.9) 0 (0.0) 0 (0.0) 78 (37.0)
Posterior wall diameter [mm] 11.3 ± 3.1**** 9.4 ± 1.9 10.5 ± 0.7 8.9 ± 1.6 10.4 ± 2.8
RWT [cm] 0.53 ± 0.17**** 0.41 ± 0.09 0.48 ± 0.11 0.38 ± 0.10 0.47 ± 0.15
ECG abnormalities [n] 42 (36.5)**** 7 (10.0) 1 (50.0) 1 (5.3) 51 (24.8)
Pacemaker [n] 18 (14.5)*** 0 (0.0) 0 (0.0) 0 (0.0) 18 (8.0)
Myocardial infarction [n] 7 (6.9)* 0 (0.0) 0 (0.0) 0 (0.0) 7 (3.5)
Renal measures
Albumin/creatinine-ratio [mg/gCreatinine] 48 [0–4773] 37 [0–734] 7 [7] 9 [0–226] 39 [0–4773]
Albuminuria [n] 60 (61.9) 30 (58.8) 0 (0.0) 6 (40.0) 96 (58.5)
Microalbuminuria (30–300 mg/gCreatinine) [n] 40 (66.7)
* 27 (90.0) 0 (0.0) 6 (100.0) 73 (76.0)
Macroalbuminuria (>300 mg/gCreatinine) [n] 20 (33.3) 3 (10.0) 0 (0.0) 0 (0.0) 23 (24.0)
Cystatin C [mg/l] 1.03 ± 0.36**** 0.78 ± 0.19 0.65 ± 0.18 0.71 ± 0.09 0.90 ± 0.32
eGFRcys [ml/min/1.73 m
2]a 80.4 ± 26.3**** 103.6 ± 20.7 116.1 ± 20.3 114.5 ± 13.6 92.6 ± 26.7
Creatinine [mg/dl] 0.99 ± 0.93*** 0.75 ± 0.15 0.64 ± 0.11 0.65 ± 0.09 0.87 ± 0.71
eGFRcreat [ml/min/1.73 m
2]a 81.2 ± 25.3**** 98.6 ± 19.1 108.8 ± 12.3 113.8 ± 12.6 90.4 ± 24.8
eGFRcreat < 90 ml/min/1.73 m
2 [n] 82 (66.1)*** 28 (36.8) 0 (0.0) 0 (0.0) 110 (49.1)
Hb [mg/dl] 13.3 ± 1.0 13.4 ± 0.99 13.1 ± 0.31 13.3 ± 1.1 13.3 ± 1.02
Dialysis [n] 2 (1.6) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.9)
Kidney transplantation [n] 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5)
Manifestations in different organs justifying ERT
(per patient) [n]
2.5 [1–5]**** 1 [1–3] - - 2 [0–5]
Categorical data are presented as n and are % of total in parenthesis. Otherwise data is presented as mean ± standard deviation or median [range]. eGFR:
estimated glomerular filtration rate (aexcluding patients with dialysis and/or kidney transplant); Hb Hemoglobin. eGFRcreat and eGFRcys are calculated via the CKD-
EPI formulas according to Levey et al. 2009 and Inker et al. 2012, respectively. LVDDi: left ventricular diastolic diameter index; LVH: left ventricular hypertrophy
(>12 mm septal diameter); NYHA New York Heart Association, RWT relative wall thickness. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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[9, 14–16]. Interestingly, in females, cardiac replacement
fibrosis can already appear at a non-hypertrophic disease
stage, being in contrast to males who generally develop
LVH prior to replacement fibrosis [36, 37]. In our study,
we did not include data on cardiac MRIs, since most of
the participating centers routinely perform echocardi-
ography but not cardiac MRI. Of note, in our subset of
68 cardiac MRIs, 41 females revealed late enhancement
as a sign of cardiac fibrosis. Interestingly, 22 femaleswith late enhancement did not yet present with LVH.
Of these, 12 were not treated with ERT. Hence, in fe-
males with FD cardiac MRIs should be routinely per-
formed to identify those with cardiac involvement,
necessitating ERT initiation [37].
In addition, protective drugs such as RAAS blockers
are needed in females (and males) with renal insuffi-
ciency, proteinuria, and LVH. In our study cohort,
RAAS blockers were given in >40 % of all females
with a >2.0-fold higher treatment frequency in
Table 3 Clinical presentation of females with and without ERT with ERT indications with nonsense and missense mutations











Age [y] 53 ± 14 53 ± 15 45 ± 15 40 ± 13
ERT duration [months] 57 ± 47 81 ± 46** - -
α-galactosidase A activity below reference [n] 24 (60.0) 18 (51.4) 11 (39.3) 13 (76.5)*
Lyso-Gb3 value [ng/ml] 6.3 ± 4.1 8.6 ± 8.0 6.9 ± 6.0 9.9 ± 5.0
Lyso-Gb3 value above reference [n] 30 (88.2) 40 (100.0)* 26 (70.3) 17 (94.4)
Angiokeratoma [n] 25 (39.7) 34 (60.7)* 10 (20.4) 10 (41.7)
Edema [n] 10 (15.4) 18 (30.5) 0 (0.0) 1 (4.2)
Gastrointestinal pain [n] 22 (33.9) 10 (17.5) 19 (40.4) 7 (29.2)
Hypohidrosis [n] 22 (34.4) 27 (47.4) 15 (29.4) 7 (29.7)
Cornea verticillata [n] 37 (63.8) 39 (67.2) 16 (50.0) 13 (65.0)
Tinnitus [n] 23 (35.9) 19 (32.2) 9 (18.8) 4 (16.7)
Hypacusis [n] 19 (24.6) 11 (19.0) 4 (8.3) 3 (13.0)
FD-related pain [n] 41 (63.1) 41 (69.5) 21 (41.2) 16 (66.7)*
Fatigue [n] 32 (50.8) 30 (51.7) 11 (21.6) 4 (16.7)
Ever TIA [n] 4 (6.4) 9 (15.8) 2 (4.1) 2 (8.3)
Ever stroke [n] 11 (19.0) 10 (19.6) 3 (5.9) 0 (0.0)
SFN [n] 10 (29.4) 12 (29.3) 3 (7.9) 6 (27.3)
Disease severity score
MSSI score 21.8 ± 12.0 19.6 ± 9.4 7.5 ± 5.3 6.9 ± 5.1
Cardiac measures
Septal diameter [mm] 11.8 ± 2.7 12.8 ± 4.4 9.6 ± 2.2 9.6 ± 1.7
LVH [n] 33 (55.0) 31 (56.4) 10 (20.0) 4 (16.7)
Posterior wall diameter [mm] 11.2 ± 2.8 11.5 ± 3.4 9.5 ± 1.9 9.1 ± 1.7
RWT [cm] 0.52 ± 0.14 0.54 ± 0.21 0.42 ± 0.10 0.39 ± 0.07
Pacemaker [n] 10 (15.4) 8 (13.6) 0 (0.0) 0 (0.0)
Myocardial infarction [n] 3 (5.7) 4 (8.3) 0 (0.0) 0 (0.0)
Renal measures
Albumin/creatinine-ratio [mg/gCreatinine] 66 [0–1148] 39 [0–4773] 37 [0–734] 36 [6–535]
Albuminuria [n] 34 (64.2) 26 (59.1) 19 (55.9) 11 (64.7)
Creatinine [mg/dl] 1.07 ± 1.24 0.89 ± 0.34 0.76 ± 0.16 0.74 ± 0.12
eGFRcreat [ml/min/1.73 m
2]a 81.3 ± 25.4 81.0 ± 25.3 96.7 ± 19.8 101.0 ± 18.4
Manifestations in different organs justifying ERT
(per patient) [n]
2 [1–5] 3 [1–4] 1 [1–3] 1 [1–3]
Nonsense mutations include single nucleotide exchanges, resulting in a stop codon (termination), deletion or insertions of nucleotides resulting in a frame shift or
large deletions within the protein, or splice site mutations, resulting in altered splice products of mRNA. Categorical data are presented as n and are % of total in
parenthesis. Otherwise data are presented as mean ± SD or median [range]. eGFR estimated glomerular filtration rate (aexcluding patients with dialysis and/or
kidney transplant), LVH Left ventricular hypertrophy, MSSI Mainz Severity Score Index, SFN small fiber neuropathy, RWT relative wall thickness, TIA transitory
ischemic attack. eGFRcreat is calculated via the CKD-EPI formula according to Levey et al. 2009. missense vs. nonsense mutations:
*p < 0.05, **p < 0.01
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(57 % vs. 24 %). In general, the frequency of renopro-
tective and cardioprotective RAAS blocker prescrip-
tion was comparable across FD centers and in
accordance with the frequencies of LVH and albumin-
uria only in females on ERT. In patients without ERT,
a similar relation was found for the presence of LVHand RAAS blockers, but not with albuminuria. Since
albuminuria/proteinuria is one of the first signs of
impaired renal function, and according to recent
KDIGO guidelines [23], persistent albuminuria is as-
sociated with poor clinical outcome a more aggressive
renoprotective intervention should be considered in
these patients.
Table 4 Differences in clinical presentation between ERT-naïve





reference (n = 16)
Females above the
reference (n = 52)
Age [y] 49 ± 15 41 ± 13*
Nonsense mutation [n] 1 (6.3) 19 (36.5)*
Lyso-Gb3 value [ng/ml] 0.9 ± 0.5 9.4 ± 5.0**
FD-related pain [n] 2 (12.5) 25 (48.1)*
Ever TIA/ stroke [n] 3 (18.8) 4 (8.0)
SFN [n] 1 (6.3) 8 (16.7)
Disease severity score
MSSI Score 4.3 ± 3.8 6.8 ± 5.9
Cardiac measures
Septal diameter [mm] 9.1 ± 1.4 9.4 ± 2.1
LVH [n] 2 (12.5) 7 (14.0)
Posterior wall
diameter [mm]
9.2 ± 1.8 9.4 ± 1.9
RWT [cm] 0.41 ± 0.09 0.40 ± 0.09




9 [5–51] 36 [0–734]
Albuminuria [n] 2 (28.6) 21 (56.8)
Creatinine [mg/dl] 0.76 ± 0.21 0.74 ± 0.13
eGFRcreat [ml/min/1.73 m




1 [0–3] 1 [0–3]
Categorical data are presented as n and are % of total in parenthesis.
Otherwise data is presented as mean ± SD or median [range]. eGFR estimated
glomerular filtration rate, LVH left ventricular hypertrophy, MSSI Mainz Severity
Score Index, RWT relative wall thickness, SFN small fiber neuropathy, TIA
Transitory ischemic attack. *p < 0.05, **p < 0.0001
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observed no clinically relevant differences concerning
FD-manifestations and disease burden between females
receiving either agalsidase-alfa or agalsidase-beta. Al-
though the relative small group of agalsidase-beta-
receiving patients might be a limitation, it seems that
physicians do not prefer any of these two drugs to treat
more severe affected female patients.
Since ERT initiation in female patients based on the
clinical presentation might be too late, a prognostic bio-
marker identifying females with a rapid disease progres-
sion is warranted. While plasma lyso-Gb3 seems to be a
useful prognostic marker to elucidate disease severity
and progression in affected males and correlates well
with ERT effectiveness [17, 38, 39], lyso-Gb3 levels are
difficult to correlate with disease burden and progression
in females and patients with non-classical GLA muta-
tions [17–19, 39]. In our study, plasma lyso-Gb3 levelsabove the reference were more frequent in females on
ERT compared to treatment-naïve females. ERT-naïve fe-
male patients with elevated lyso-Gb3 levels showed com-
parable incidences of organ manifestations and a higher
frequency of FD-related pain, even if they were 8 years
younger than females with normal lyso-Gb3 levels.
Therefore, our preliminary data suggest that elevated
plasma lyso-Gb3 levels in females also seem to be a
marker of disease burden. However, further longitudinal
observational studies are warranted to clarify the prog-
nostic value of lyso-Gb3 in ERT-naïve females with dif-
ferent lyso-Gb3 levels.
In contrast to most males, females with FD present
with a heterogeneous clinical picture and variable dis-
ease progression, independent of the presence of a non-
sense or a missense mutation. Our results demonstrate
that although females with missense mutations seem to
have a lower risk to suffer from severe FD-typical mani-
festations and events justifying ERT in general, the
disease burden in once affected patients is similar, inde-
pendent of the disease-causing underlying GLA muta-
tion (i.e. nonsense or missense). The variation and the
missing genotype-phenotype correlation might be due to
the controversially discussed X-chromosomal inactiva-
tion. While Elstein and colleagues did not find any asso-
ciations with clinical signs in 77 females FD patients
analyzed for skewed X-inactivation [40], Echevarria and
colleagues demonstrated significant differences in dis-
ease progression depending on the direction and degree
of X-inactivation in 56 patients [41]. In that respect, also
larger longitudinal studies are warranted to confirm
these results and to demonstrate an effect of skewed X-
chromosomal inactivation on FD phenotype in affected
females.
Conclusions
We conclude that the treatment concept for females
with FD in Germany is in line with the current European
Fabry guidelines. However, a relevant number of females
remain untreated despite organ involvement, necessitat-
ing a careful reevaluation of these females. Elevated
plasma lyso-Gb3 levels in females seem to be a marker
of disease burden, even if the prognostic value of ele-
vated lyso-Gb3 levels for ERT initiation in females needs
evaluation in future observational studies.
Limitations
The intention of this study was to present a current
clinical overview of females with FD and their treatment
status and to assess the implementation of current Euro-
pean FD guidelines [13] for ERT treatment. Analysis and
readout of techniques such as echoes have been per-
formed within each center by the same on-side special-
ized operators, which limits intra-center variations.
Lenders et al. Orphanet Journal of Rare Diseases  (2016) 11:88 Page 10 of 11However, slight variations between participating centers
cannot be fully excluded. In addition, some parameters
such as plasma lyso-Gb3 or GLA activity were not avail-
able for the entire study cohort. Since no longitudinal
analysis starting with treatment-naïve baselines has been
performed and treatment regimens of agalsidase-alfa and
-beta groups were heterogeneous, no comparisons of
effectiveness between agalsidase-alfa or-beta could be
drawn.
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